Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levobupivacaine + mepivacaine is an investigational combination of two amide-type local anesthetics used for regional anesthesia and postoperative pain management. Levobupivacaine is the S(-)-enantiomer of bupivacaine, providing long-acting sensory and motor blockade, while mepivacaine is an intermediate-acting agent. Both drugs function by binding to and inhibiting voltage-gated sodium channels (Nav) on the neuronal membrane, preventing the initiation and conduction of nerve impulses. This combination is primarily studied in the context of nerve blocks (such as femoral, saphenous, or i-pack blocks) for patients undergoing total knee replacement surgery to optimize analgesic efficacy and recovery.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levobupivacaine + mepivacaine.